Evaluating Pelvic Floor Muscle Rehabilitation with Desmopressin for Treating Bedwetting in Children Ages 7 to 13

What this Trial Is About

Researchers are investigating the effects of Structured Pelvic Floor Muscle Rehabilitation SPFMR combined with desmopressin acetate DDAVP treatment in children aged 7 to 13 with Primary Monosymptomatic Nocturnal Enuresis PMNE, a condition characterized by bedwetting without daytime urinary symptoms. This randomized controlled trial aims to determine if adding SPFMR can reduce the frequency and severity of bedwetting episodes and lower relapse rates during both short- and long-term follow-ups compared to DDAVP treatment alone. The study has two groups one receiving only DDAVP and urotherapy training as prescribed by a pediatric urologist, and the other receiving DDAVP plus 10 weeks of structured pelvic floor muscle rehabilitation sessions led by a physiotherapist. The rehabilitation includes diaphragmatic breathing, biofeedback-assisted pelvic floor training, core stabilization and squat exercises, strengthening of specific muscles, balance training, and home exercises. Each rehabilitation session lasts about 60 minutes, with home exercises performed three times weekly. Participants will keep diaries documenting bedwetting frequency and severity and undergo assessments such as uroflowmetry, post-void residual measurement, bladder diaries, and pelvic floor muscle activation evaluations at baseline and several follow-up points. Researchers will monitor treatment responses and relapse rates over time. The study follows ethical guidelines, requires parental consent, and expects to conclude in 2027.

Effectiveness of Pelvic Floor Muscle Rehabilitation Combined With Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis